Abstract
Background The endogenous opioid system is thought to play a role in the placebo antidepressant response. A recent trial comparing the rapid antidepressant effects of ketamine versus placebo in surgical patients, some of whom were on chronic opioid therapy, revealed a substantial placebo effect. This finding provided an opportunity to test the hypothesis that opioid agonist exposure interacts with placebo antidepressant responses.
Methods This post hoc analysis utilized data from a previously reported randomized, anesthesia-blinded, placebo-controlled trial of intravenous ketamine in depressed patients undergoing routine surgery. Mixed-effects models were used to determine whether baseline opioid use influenced antidepressant responses to the trial interventions, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) over 1 to 14 days post-treatment.
Results The analysis showed that baseline opioid use significantly reduced post-treatment depression severity in patients who received placebo, but not in those who received ketamine. This reduction was independent of baseline depression severity, baseline pain intensity, and ethnicity. Additionally, there was negligible correlation between postoperative pain intensity and depression severity.
Limitations This analysis was unregistered and conducted on a small sample; the findings need to be confirmed by prospective controlled studies.
Conclusions Opioid use at baseline attenuated the placebo antidepressant response independently of pain in depressed patients who received the study treatment under general anesthesia for routine surgery. The antidepressant response was preserved in opioid users who received intravenous ketamine.
Competing Interest Statement
Boris D. Heifets reports board memberships with Osmind and Journey Clinical. Alan F. Schatzberg has consulting or advisory roles and/or equity stakes with Alto Neuroscience, ANeuroTech, Compass Pathways, Magnus, Neurawell, Parexel, Sage, Signant Health, Corcept Therapeutics, Delpor, Madrigal Pharmaceuticals, Seattle Genetics, Titan, and Xhale. The other authors declare no competing financial interests or personal relationships that could have influenced the work.
Clinical Trial
NCT03861988
Clinical Protocols
Funding Statement
This work was supported by a grant awarded to Boris D. Heifets by the Society for Neuroscience in Anesthesiology and Critical Care. Theresa R. Lii received salary support through a T32 grant from the NIH National Institute on Drug Abuse [T32DA035165] and the National Institute of General Medical Sciences [T32GM089626].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this study was granted by the Institutional Review Board of Stanford University.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
De-identified participant data, accompanying data dictionaries, the study protocol, and the statistical analysis plan are accessible at https://osf.io/zdkr8/. All participants provided consent for their de-identified data to be shared with external entities for scientific research purposes.
